Sector News

Tergus Pharma to become full-fledged CDMO with new manufacturing facility

June 12, 2019
Life sciences

A small company that is all about the development of dermatology drugs has snagged a new investor and will soon start on a manufacturing facility that will catapult it into the CDMO market.

Tergus Pharma says an investment from private equity investor Great Point Partners will allow it to build its first commercial manufacturing facility. The Durham, North Carolina-based company currently provides topical formulation development, in vitro permeating testing, clinical trial materials and other services.

“For years we have discussed building a commercial facility. The equity capital from GPP will enable us to do this,” Tergus CEO Vijendra Nalamothu said in a statement.

Construction of the 100,000 square foot operation is slated to begin next month and to be complete in 2020, the company said. Terms of the deal were not disclosed.

The investment comes as the dermatology market is undergoing big changes. Nestle last month announced it is in exclusive talks to sell its skin health unit for about $10.1 billion to a consortium led by private equity EQT Partners. That comes just five years after the Swiss company moved deeper into the skin products to diversify away from slower sales in food.

The investors will pick up prescription brands including acne topical treatment Epiduo, as well as aesthetic and consumer products. About 5,000 employees also are expected to move.

Novartis is in the process of selling its Sandoz U.S. dermatology business, a dermatology development center and about 300 generics to India’s Aurobindo Pharma. Bayer in 2018 offloaded its prescription dermatology portfolio to Dutch company LEO Pharma.

By Eric Palmer

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend